Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 16 of 16

List	Outcome	Time frame	Description
Primary	Incidence and severity of AEs in IIM.	3 months after CAR infusion.	Incidence and severity of AEs in Idiopathic inflammatory myopathies
Primary	Incidence and severity of AEs in IIM.	6 months after CAR infusion.	Incidence and severity of AEs in Idiopathic inflammatory myopathies.
Primary	Incidence and severity of AEs in IIM.	12 months after CAR infusion.	Incidence and severity of AEs in Idiopathic inflammatory myopathies.
Primary	Incidence and severity of AEs in IIM.	24 months after CAR infusion.	Incidence and severity of AEs in Idiopathic inflammatory myopathies.
Primary	Incidence and severity of AEs in DCSS	3 months after CAR infusion.	Incidence and severity of AEs in diffuse cutaneous systemic sclerosis
Primary	Incidence and severity of AEs in DCSS	6 months after CAR infusion.	Incidence and severity of AEs in diffuse cutaneous systemic sclerosis
Primary	Incidence and severity of AEs in DCSS	12 months after CAR infusion.	Incidence and severity of AEs in diffuse cutaneous systemic sclerosis
Primary	Incidence and severity of AEs in DCSS	24 months after CAR infusion.	Incidence and severity of AEs in diffuse cutaneous systemic sclerosis
Primary	Incidence and severity of AEs in SLE Nephritis	3 months after CAR infusion.	Incidence and severity of AEs in systemic lupus erythematosus nephritis.
Primary	Incidence and severity of AEs in SLE Nephritis	6 months after CAR infusion.	Incidence and severity of AEs in systemic lupus erythematosus nephritis.
Primary	Incidence and severity of AEs in SLE Nephritis	12 months after CAR infusion.	Incidence and severity of AEs in systemic lupus erythematosus nephritis.
Primary	Incidence and severity of AEs in SLE Nephritis	24 months after CAR infusion.	Incidence and severity of AEs in systemic lupus erythematosus nephritis.
Primary	Incidence and severity of AEs in AAV	3 months after CAR infusion.	Incidence and severity of AEs in ANCA-Associated vasculitis
Primary	Incidence and severity of AEs in AAV	6 months after CAR infusion.	Incidence and severity of AEs in ANCA-Associated vasculitis
Primary	Incidence and severity of AEs in AAV	12 months after CAR infusion.	Incidence and severity of AEs in ANCA-Associated vasculitis
Primary	Incidence and severity of AEs in AAV	24 months after CAR infusion.	Incidence and severity of AEs in ANCA-Associated vasculitis

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06152172/registered

API reference For AI assistants